Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LTI-03

Peptide · Acts on Caveolin-1 (CAV1) · developed by Rein Therapeutics

Phase 2 Most advanced trial

RNTX Developer

2 Registered trials

What is LTI-03?

LTI-03 is a 7-amino acid peptide derived from the caveolin-1 scaffolding protein, administered as a dry powder by inhalation. It is being studied in idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: Caveolin-1 (CAV1)
Mechanism: Acts on Caveolin-1 (CAV1)
Therapy area: Respiratory
Developer: Rein Therapeutics (RNTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: JE7G34JYW4

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06968845	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)	Recruiting	RNTX
NCT04233814	Phase 1	Idiopathic Pulmonary Fibrosis	Completed	RNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis

More from Rein Therapeutics

Nasaruplase Gamma Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the RNTX page.

Follow RNTX, the company behind LTI-03

See RNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z